Citius Pharmaceuticals 株価情報 (NASDAQ: CTXR)

最新ニュース Citius Pharmaceuticals (NASDAQ:CTXR) 株価情報

CITIUS PHARMACEUTICALS INC

Citius Pharma

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals Inc

The FTX Recovery Trust will distribute more than $5 billion to creditors starting May 30, as part of its second payout under the <a href="https://www.benzinga.com/markets/cryptocurrency/22/11/29681030/ftx-files-for-chapter-11-bankruptcy">Chapter 11 bankruptcy plan</a>.
This marks a significant step in addressing claims from the collapse of FTX, the cryptocurrency exchange that <a href="https://www.benzinga.com/markets/cryptocurrency/22/12/30093147/you-think-ftx-was-bad-investors-suffered-far-greater-losses-from-terra-report">imploded in November 2022.</a>
The FTX collapse, one of the largest failures in crypto history, stemmed from allegations of mismanagement and fraud under former CEO Sam Bankman-Fried. 
The exchange, once valued at $32 billion, filed for bankruptcy after a liquidity crisis exposed a shortfall in customer funds. 
Bankman-Fried was later convicted of fraud, misappropriating $10 billion in customer assets, leading to a 25-year prison sentence. 
The fallout left thousands of customers and creditors awaiting repayment, with the Recovery Trust tasked with recovering and distributing assets.
The second distribution <a href="https://www.prnewswire.com/news-releases/ftx-recovery-trust-to-distribute-more-than-5-billion-to-creditors-in-second-distribution-on-may-30-2025-302456976.html">targets</a> holders of allowed claims in various classes who have met pre-distribution requirements. 
Funds will be disbursed through Bitgo or Kraken, with payments expected within one to three business days from May 30. 
John J. Ray III, the plan administrator, described the distribution as a milestone, noting the complexity of managing claims for a vast creditor base. He emphasized ongoing efforts to recover additional assets and resolve remaining claims.
Eligible creditors must complete Know Your Customer verification, submit tax forms, and onboard with a distribution service provider via the FTX Customer Portal. 
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45444794/bitcoin-is-starting-to-outperform-gold-jpmorgan">Bitcoin Is Starting To Outperform Gold: JPMorgan</a>
Those with transferred claims must ensure their details are updated with the claims agent. FTX warned of phishing scams, advising customers to verify communications and avoid connecting wallets to suspicious sites.
The distribution prioritizes different claim classes, with convenience claims receiving 120%, while customer and unsecured claims range from 54% to 72%. 
Future distribution dates will be announced, with similar requirements for eligibility. Separately, FTX Digital Markets Ltd. will handle claims for its customers.
FTX's downfall began when a November 2022 report revealed that Alameda Research, a hedge fund linked to Bankman-Fried, held significant illiquid assets tied to FTX's native token, FTT. 
A subsequent run on customer withdrawals exposed FTX's inability to cover deposits, triggering bankruptcy. 
Investigations uncovered that customer funds were misused to cover Alameda's losses, leading to <a href="https://www.benzinga.com/markets/cryptocurrency/22/11/29691585/why-ftxs-collapse-is-the-crypto-equivalent-of-the-2008-lehman-brothers-crisis">widespread financial harm</a>.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45441997/coinbase-hit-by-data-breach-refuses-to-pay-20m-ransom">Coinbase Hit By Data Breach, Refuses To Pay $20M Ransom</a></li>
</ul>
Image: Shutterstock

FTX To Distribute Over $5B To Creditors In Second Round Of Payouts On May 30

Needham analyst Mike Cikos reiterated the Buy rating on CoreWeave, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) on Thursday, <a target="_blank" href="https://www.benzinga.com/quote/CRWV/analyst-ratings" rel="noreferrer noopener">with a price forecast of $55.</a>
The company reported its first quarterly results as a public<a target="_blank" href="https://www.benzinga.com/25/05/45436747/coreweave-stock-is-volatile-thursday-whats-going-on" rel="noreferrer noopener"> company late Wednesday.&nbsp;</a>
CoreWeave said first-quarter revenue increased 420% year-over-year to $981.63 million, beating analyst&nbsp;<a target="_blank" href="http://benzinga.com/quote/crwv/earnings" rel="noreferrer noopener">estimates</a>&nbsp;of $859.77 million. The&nbsp;Nvidia-backed AI infrastructure company reported an adjusted loss of approximately 60 cents per share.
Cikos noted that CoreWeave's earnings highlighted a significant market opportunity and solid execution. Revenue surpassed expectations by 15%, and second-quarter guidance came in 9% above consensus at the midpoint.
Also Read: <a target="_blank" href="https://www.benzinga.com/economics/macro-economic-events/25/05/45435725/tariffs-slow-retail-spending-as-producer-prices-post-sharpest-drop-since-2020" rel="noreferrer noopener">Tariffs Slow Retail Spending As Producer Prices Post Sharpest Drop Since 2020</a>
Cikos added that full-year revenue guidance was raised by 7%—fully incorporating the first-quarter beat, the second-quarter raise, and an implied increase for the second half of the year.
The analyst observed growing enterprise AI adoption, reflected in rising inference demand, which has encouraged management to accelerate investment, as data center capacity expanded from 1.3GW to 1.6GW.
While Cikos sees some stock volatility as investors digest the debt implications tied to funding CapEx, the analyst highlighted that CoreWeave has excelled in securing GPUs and assembling data center infrastructure in a highly constrained power environment, enabling it to gain market share amid soaring demand for AI compute.
He emphasized the company's bold and effective strategy for securing data center power—now at 360 active megawatts with over 1.3GW under contract—driven by flexible partnerships and innovative financing, including upfront CapEx to accelerate deployment timelines.
Cikos writes that the market may be underestimating the longevity of CoreWeave's infrastructure returns, noting that while GPUs are depreciated over six years, management sees a cash payback period of roughly 2.5 years and average contract durations of around four years.
The analyst added that the company could potentially realize value from its infrastructure well beyond the initial contract terms.
Price Action: CRWV shares are trading higher by 5.08% to $70.89 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45430835/us-stocks-likely-to-open-lower-after-sp-500s-three-day-winning-streak-many-uncertainties-remain-says-expert" target="_blank" rel="noreferrer noopener">US Stocks Likely To Open Lower After S&amp;P 500's Three-Day Winning Streak: ‘…Many Uncertainties Remain,' Says Expert</a></li>
</ul>
Image: Shutterstock

Equities

News

Markets

Analyst Ratings

Movers

Trading Ideas

General

CRWV

CoreWeave Gears Up For AI Growth, But Debt Concerns May Jolt Stock, Says Analyst

WIIM

SDOT

SDOT stock has given up its prior gain. Sadot Group shares were trading higher following Q1 reported financial results.

TSHA

Taysha Gene Therapies shares are trading higher following Q1 earnings.

XPOF

Xponential Fitness shares are trading lower after the company announced CEO Mark King will retire.

GRAL

GRAIL shares are trading higher after the company reported Q1 financial results.

Needham analyst Ryan Koontz reiterated a buy rating and a $130 <a href="https://www.benzinga.com/quote/ANET/analyst-ratings" target="_blank" rel="noopener">price target </a>for Arista Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) on Thursday.
Last Friday, Koontz hosted Chantelle Breithaupt, Arista Networks CFO, in a Fireside Chat.
Breithaupt reviewed the company&#8217;s strong first-quarter results and second-quarter guidance last week and its approach to fiscal year guidance, which was notably conservative and disappointed investors.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45267908/aristas-stock-hit-as-analysts-cut-targets-over-tariff-uncertainty-despite-strong-ai-demand" rel="noreferrer noopener">Arista&#8217;s Stock Hit As Analysts Cut Targets Over Tariff Uncertainty Despite Strong AI Demand</a>
He dove into the impact of tariffs and various approaches the company is already taking to mitigate the effects.
With investor attention squarely on progress in the AI back-end pilot, he assured meaningful progress on all four major customers. He affirmed that recent growth in Deferred Revenue was at least partially due to these pilots.
After raising calendar 2025 revenue guidance to 17% last quarter, management reiterated 17% growth due to the recent tariff and macro uncertainty.
Breithaupt provided additional context, noting that uncertainty has a greater impact on the business&#8217;s cost structure than the top line.
Due to long lead times and customer orders, Arista Networks conveys strong visibility for demand through calendar 2025, and discussions for calendar 2026 have not indicated any signs of a slowdown.
Koontz provided more details on the results for the first quarter of 2025.
Management estimates proposed tariff policies to have a 100-150 bps impact on gross margins, assuming no (further) mitigation.
Arista Networks has primary manufacturing operations in Mexico and Malaysia, which can provide flexibility with USMCA if specific requirements are met.
Given its scale, Arista Networks has powerful relationships with its CMs and respectable fungibility, but significant changes would still likely take six months to complete supply chain shifts.
Management continuously discusses expectations and mitigation tactics, noting that raising prices for customers would be their last resort but always a possibility.
Breithaupt also noted that product inventory increased sequentially in the recent quarter to buffer the impacts of possible future tariffs, and the company intends to leverage its massive balance sheet as a mitigation tool.
He reiterated that the $750 million front-end and back-end AI targets for calendar 2025 remained unchanged, and the four pilots are on track to build towards 100K GPU clusters in calendar 2025 or early calendar 2026.
Deferred revenue has attracted considerable attention in recent quarters, increasing ~$300 million sequentially and $1.4 billion year over year in the first quarter of 2025.
Arista Networks explains this is due to a combination of new products, use cases, and customers from AI, which can take 12-18 months to approve and deploy fully.
New customers often take longer to scale consumption, and longer lead times with chips result in larger purchase commitments.
Price Action:&nbsp;ANET stock is down 2.51% at $95.75 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/tech/25/05/45261116/cisco-unveils-quantum-chip-and-lab-to-push-next-gen-networking" target="_blank" rel="noreferrer noopener">Cisco Unveils Quantum Chip And Lab To Push Next-Gen Networking</a></li>
</ul>
Photo: Shutterstock

Price Target

Reiteration

ANET

Arista Networks Gains Analyst Backing On AI Momentum, Strong Deferred Revenue And Demand Visibility

Two executives with ties to President Donald Trump and Trump Media &amp; Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) have a new SPAC offering targeting <a href="https://www.benzinga.com/news/ipos/25/03/44367379/global-client-advisory-group-affiliate-files-for-175-million-ipo-targeting-crypto-digital-security-ventures">the cryptocurrency market.</a>
With several stocks soaring on recent crypto-related mergers, could this be a SPAC to watch?
The SPAC Offering: On Thursday, Renatus Tactical Acquisition Corp I (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTACU#NASDAQ">RTACU</a>) began trading. The units consist of one common share (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTAC#NASDAQ">RTAC</a>) and one-half of a redeemable warrant (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTAW#NASDAQ">RTAW</a>).
After announcing a 17.5 million offering at $10 per unit to raise $175 million, the offering was upsized to 21 million shares <a href="https://www.businesswire.com/news/home/20250513920321/en/Renatus-Tactical-Acquisition-Corp-I-Announces-Pricing-of-Upsized-%24210-Million-Initial-Public-Offering">raising </a>$210 million.
While SPACs have received less attention in recent years, this particular blank check company, given its two names attached, could quickly attract investors&#8217; attention.
Among the names involved in the sponsor companies of the SPAC deal are Eric Swider and Devin Nunes. Swider is the former CEO of Digital World Acquisition Corporation. The company, referred to as DWAC, was a SPAC that took Trump's media company Trump Media &amp; Technology Group public. 
Swider and Nunes currently <a href="https://ir.tmtgcorp.com/corporate-governance/board-of-directors/">serve </a>as director and CEO of Trump Media &amp; Technology Group, respectively. For the new SPAC, Swider <a href="https://www.sec.gov/edgar/browse/?CIK=0002035173">serves</a> as CEO while Nunes is chairman.
SPAC expert and Accelerate CEO Julian Klymochko <a href="https://x.com/JulianKlymochko/status/1922987358086893655">highlighted </a>the offering in a tweet Thursday.
"The former CEO of $DWAC, Eric Swider, along with the current CEO of $DJT, Devin Nunes, launched a new SPAC, Renatus Tactical Acquisition I. It IPO'd today. Its focus is on the crypto industry in the U.S. It's one to watch!" Klymochko tweeted.
Read Also: <a href="https://www.benzinga.com/24/12/42498758/truth-social-ceo-nunes-to-head-trumps-intelligence-advisory-board">Truth Social CEO Nunes to Head Trump&#8217;s Intelligence Advisory Board</a>
The SPAC Target Market: The SPAC could target a merger in any industry, sector or geographic region. However, the prospectus indicates a focus on finding a company in the cryptocurrency or blockchain space in the United States. Data security and dual-use technologies are also listed as potential target areas for a deal.
"We intend to capitalize on the ability of our management team to identify, acquire and operate a business or businesses that can benefit from our management team's established global relationships, sector expertise and active management and operating experience," the prospectus reads.
The SPAC is targeting a company valued between $500 million and $5 billion.
The prospectus also highlights Trump's positive push for cryptocurrency and the growing market opportunity for Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and other cryptocurrencies. It recalls the recent executive order to create a strategic Bitcoin reserve by <a href="https://www.benzinga.com/25/03/44183572/trump-establishes-strategic-bitcoin-reserve-funded-by-forfeited-assets-i-made-the-promise">stockpiling cryptocurrency assets</a>. 
Why It's Important: The timing of the public offering could be a strong setup for the management team and investors with several recent crypto-related merger announcements seeing shares trade significantly higher and receive increased attention.
Here are some of the recent deals:
<ul class="wp-block-list">
<li>Bitcoin holding company Twenty One <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44975441/cantor-fitzgerald-backed-twenty-one-launches-strategy-rival-at-3-billion-valuation">announced a SPAC merger</a> with Cantor Equity Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEP#NASDAQ">CEP</a>) with a target of holding 42,000 Bitcoin. The merger includes backing from Tether, SoftBank Group and Jack Mallers, who will serve as CEO. After the merger, the company will trade as "XXI" on the Nasdaq and could be one of the largest public holders of Bitcoin.</li>
<li>Asset Entities (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASST#NASDAQ">ASST</a>) <a href="https://www.benzinga.com/news/contracts/25/05/45260992/asset-entities-stock-rockets-higher-on-merger-deal-to-form-bitcoin-treasury-company">announced a merger</a> with Strive Asset Management to become a public Bitcoin holding company on the Nasdaq.</li>
<li>Nakamoto Holdings <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45352237/nakamoto-holdings-raises-710m-merges-with-kindlymd-to-build-bitcoin-treasury-holding-company">announced a merger</a> with Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) in a deal that will see the newly formed company be a Bitcoin holding company. Nakamoto comes from the mind of Bitcoin Magazine CEO and Trump crypto advisor David Bailey, who will serve as CEO.</li>
<li>Gryphon Digital Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) recently <a href="https://www.benzinga.com/news/small-cap/25/05/45347101/gryphon-digital-to-take-trump-affiliated-american-bitcoin-public-in-merger-deal-stock-soars">announced a merger </a>with American Bitcoin, a subsidiary of Hut 8 Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>). American Bitcoin was launched in collaboration between Hut 8 and Eric Trump earlier this year. The new company will trade on the Nasdaq with the ticker "ABTC."</li>
</ul>
While not all of these were SPAC mergers, these stocks all saw shares trade higher on deal announcements, illustrating investors appetite for crypto-related mergers.
Price Action: Renatus Tactical Acquisition Corp units trade at $10.88 Thursday and have traded between $10.60 and $10.99 since going public.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/21/12/24526791/5-things-you-might-not-know-about-devin-nunes-ceo-of-trump-media-technology-group">5 Things You Might Not Know About Devin Nunes, CEO Of Trump Media &amp; Technology Group</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

IPOs

$BTC

ASST

GRYP

KDLY

RTAC

RTACU

RTAW

Trump Insiders Want A Piece Of Crypto, SPAC Action: Is A Merger Coming?

Deere &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) shares are trading higher at the last check on Thursday after the company reported second-quarter net sales and revenue fell 16% year-over-year to $12.76 billion, topping the consensus <a href="https://www.benzinga.com/news/earnings/25/05/45441833/deere-shares-rise-after-q2-beat-despite-steep-sales-declines-across-segments" target="_blank" rel="noreferrer noopener">estimate of $10.79 billion</a>.
The company expects FY25 net income to be between $4.75 billion-$5.5 billion <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">(prior $5 billion and $5.5 billion)</a>.
Goldman Sachs analyst Jerry Revich reiterated a Buy rating <a target="_blank" href="https://www.benzinga.com/quote/DE/analyst-ratings" rel="noreferrer noopener">and price forecast of $583</a>.
The analyst&#8217;s rating reflects expected Machinery capital stock growth, end of new equipment destocking, faster Precision Ag adoption, and reduced tariff margin risk.
The analyst views Deere's second-quarter results as consistent with adjusted expectations following the Machinery earnings announcement.
This reflects a margin guidance reduction of about 100 bps, likely due to tariffs impacting Construction &amp; Forestry, and a second-quarter earnings beat on 35% decremental margins (vs. GS: 46% estimate).
Also, the analyst highlighted dealers increasing inventories ahead of normal seasonality for the first time in seven quarters, suggesting the end of destocking.
Investors can gain exposure to the stock via iShares MSCI Agriculture Producers ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEGI#NYSE">VEGI</a>) and Global X AgTech &amp; Food Innovation ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROP#NASDAQ">KROP</a>).
Price Action: DE shares are up 3.08% at $522.15 at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45430835/us-stocks-likely-to-open-lower-after-sp-500s-three-day-winning-streak-many-uncertainties-remain-says-expert" target="_blank" rel="noreferrer noopener">US Stocks Likely To Open Lower After S&amp;P 500&#8217;s Three-Day Winning Streak: &#8216;&#8230;Many Uncertainties Remain,&#8217; Says Expert</a></li>
</ul>
Image: Shutterstock

Large Cap

KROP

VEGI

Green Light For Deere: Analyst Sees Growth Ahead Despite Tariff Concerns

Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) recent surge to $104,000 has been driven primarily <a href="https://www.benzinga.com/money/bitcoin-price-prediction">by spot accumulation</a> and a notable reduction in sell-side pressure, according to Glassnode's market report released Thursday.
What Happened: A key short-term support level has emerged around $93,000–$95,000, with both on-chain and exchange data suggesting that recent buyers are defending this cost basis zone.
&#8220;A key accumulation zone emerged between $93k and $95k,&#8221; the report <a href="https://insights.glassnode.com/the-week-onchain-week-19-2025/?utm_campaign=WoC_19_25&amp;utm_medium=email&amp;utm_source=newsletter">notes</a>, adding that this range aligns closely with the Short-Term Holder (STH) cost basis, which includes investors who entered the market in the past five months.
Glassnode analysts highlight that this zone is likely to act as a structural support during pullbacks. "This range&#8230; represents a demand zone where investors are likely to see value once again," they wrote.
Supporting this, net buying pressure has intensified on U.S. exchange Coinbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), while selling on Binance has sharply declined. "Coinbase has experienced a regime of consistent net buying&#8230; Binance markets have transitioned from intense net selling&#8230; to a milder -$9M daily today."
In derivatives markets, perpetual futures open interest has dropped by 10% from its peak, signaling a short squeeze and cleansing of excessive short-side leverage. 
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45438872/want-to-copytrade-the-trump-linked-world-liberty-financial-portfolio-dont-be-so-sure">Want To Copytrade The Trump-Linked World Liberty Financial Portfolio? Don&#8217;t Be So Sure</a>
WHy It MattersL This positions the market for a more sustainable uptrend.
"These types of shakeouts are characteristic of healthy resets&#8230; often seen during the early phases of a new market trend," the report states.
While ETF inflows have slowed from a peak of $389 million/day to around $58 million/day, demand remains strong. Glassnode points out that this institutional participation reflects a longer-term conviction in Bitcoin, echoing inflow patterns from earlier rallies in 2024.
Options market data also shows traders leaning bullish. 
The 1-month 25 Delta Skew stands at -6.1%, indicating traders are paying more for calls than puts, a classic sign of upside speculation.
The report further states that Bitcoin's upward momentum is well-supported. 
As long as the cost basis support zone holds and derivatives markets continue to stabilize, the rally may remain intact even as the asset approaches its all-time high near $109,000.
Read Next: 
<ul class="wp-block-list">
<li><a style="font-weight: bold;" href="https://www.benzinga.com/markets/cryptocurrency/25/05/45433455/arthur-hayes-predicts-bitcoin-to-hit-1-million-by-2028">Arthur Hayes Predicts Bitcoin To Hit $1 Million By 2028</a></li>
</ul>
Image: Shutterstock

COIN

Bitcoin Rally Supported By $95,000 Cost Basis Zone: Report

Goldman Sachs analyst James Yaro discusses the performance of retail <a href="https://www.benzinga.com/crypto" target="_blank" rel="noreferrer noopener">brokers and investment bank stocks in his coverage</a>.
Retail Broker Sector: In particular, the analyst noted that Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) and Interactive Brokers Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>) witnessed an average rise of about 35% since April 1, 2025, significantly outperforming the S&amp;P 500 by 31 percentage points.
Yaro writes that this indicates ongoing optimism about the retail trading environment, supported by robust April metrics.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/cryptocurrency/25/05/45441997/coinbase-hit-by-data-breach-refuses-to-pay-20m-ransom" rel="noreferrer noopener">Coinbase Hit By Data Breach, Refuses To Pay $20M Ransom</a>
The analyst says he remains positive on retail trading, noting that current levels are still considerably below historical highs when adjusted for account growth.
Yaro estimates 12%/5% revenue and EPS CAGRs from 2024-2027, driven by robust account acquisition, strong assets gathering, and a cyclically supportive retail trading environment.
Yaro projects compound annual growth rates (CAGRs) of 12% for revenue and 5% for EPS from 2024 to 2027, based on strong new account acquisition, robust asset gathering, and a cyclically supportive retail trading environment.
Investment Bank Sector: Stocks are up 7% since the same date, slightly outperforming the S&amp;P 500 by three percentage points, adds the analyst.
Yaro says that the cyclical recovery in investment banking appears to have been delayed again, with disclosed industry M&amp;A fees down 34% quarter-to-date year-over-year and ECM/DCM volumes falling 44%/41% in April year-over-year.
The analyst adds that the market likely needs more concrete signs of an investment banking recovery for the stocks to continue outperforming from this point on.
Given the base case scenario of limited mergers and acquisitions activity this year, the analyst anticipates a modest 3% year-over-year increase in total revenue for 2025.
In the near term, the analyst&#8217;s model forecasts a 2% quarter-over-quarter revenue decline for the second quarter of 2025.
Nevertheless, Yaro maintains a positive outlook for the medium term, projecting revenue growth of 16% in 2026 and 10% in 2027.
Overall, he views companies with more consistent structural growth prospects as positive, including Buy-rated Houlihan Lokey, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLI#NYSE">HLI</a>), HOOD, and IBKR.
Yaro also favors companies with an underappreciated counter-cyclical business, such as our Buy-rated Evercore Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVR#NYSE">EVR</a>), and companies with the potential to gain market share, which includes all four mentioned.
In particular, he anticipates a strong trading environment to support HOOD and IBKR, while HLI should experience through-the-cycle growth from ongoing momentum in Corporate Finance and benefits from restructuring and inorganic growth execution.
Yaro forecasts EVR to deliver best-in-class revenue growth from 2025 to 2027 and sees potential upside for EVR through its exposure to Equity Capital Markets (ECM).
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45415288/coinbase-ceo-brian-armstrong-invites-doge-staff-to-create-a-more-efficient-financial-system" target="_blank" rel="noreferrer noopener">Coinbase CEO Brian Armstrong Invites DOGE Staff To &#8216;Create A More Efficient Financial System&#8217;</a></li>
</ul>
Photo: Shutterstock

HOOD

IBKR

Analyst Predicts Double-Digit Revenue Growth For Retail Brokers, Noting Weak M&A, ECM/DCM Volumes In Investment Banking Sector

AppLovin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) shares are down 2.8% to $366.06 on Thursday but remain up nearly 50% over the past month, as investors might be taking profits following a sharp post-earnings rally.
What To Know: The pullback comes after the stock <a href="https://www.benzinga.com/news/25/05/45380609/applovin-stock-surges-on-strong-q1-earnings-and-tariff-truce-tailwinds">surged</a> over the past week, fueled by better-than-expected first-quarter results and a broader tech rally sparked by <a href="https://www.benzinga.com/government/regulations/25/05/45347089/wall-street-rips-higher-as-tariff-truce-halts-us-china-economic-escalation">easing</a> U.S.-China trade tensions.
Last Wednesday, AppLovin <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45323056/applovins-rapid-ad-growth-ai-gains-drive-hike-in-analyst-price-forecast">reported</a> first-quarter revenue of $1.48 billion, beating consensus estimates of $1.38 billion and growing 40% year-over-year. Adjusted EPS of $1.67 also topped forecasts.
Read Also: <a href="https://www.benzinga.com/news/25/05/45445582/plug-power-stock-hits-a-new-52-week-low-whats-going-on">Plug Power Stock Hits A New 52-Week Low: What&#8217;s Going On?</a>
The advertising segment led performance with 71% revenue growth and record 81% EBITDA margins. The company guided second-quarter ad revenue to $1.195–$1.215 billion and adjusted EBITDA to $970M–$990M, well above Street expectations.
Analysts <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45323056/applovins-rapid-ad-growth-ai-gains-drive-hike-in-analyst-price-forecast">responded</a> favorably. BofA reiterated a Buy with a $580 target, while Goldman Sachs and JPMorgan raised targets to $435 and $355, respectively.
Macro conditions have added some support this week, with Monday's news of a 90-day U.S.-China tariff rollback easing recession and inflation fears. April CPI data released Tuesday showed inflation cooling slightly, reinforcing market optimism.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45435725/tariffs-slow-retail-spending-as-producer-prices-post-sharpest-drop-since-2020">Tariffs Slow Retail Spending As Producer Prices Post Sharpest Drop Since 2020</a>
<h2 class="wp-block-heading">How To Buy APP Stock</h2>
By now you're likely curious about how to participate in the market for AppLovin &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of AppLovin, which is trading at $366.06 as of publishing time, $100 would buy you 0.27 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, APP has a 52-week high of $525.04 and a 52-week low of $60.67.

AppLovin (APP) Stock Pulls Back Following Recent 50% Surge: What's Going On?

It is that time again.
13Fs are beginning to flow into the SEC offices, and the mojo wires are burning up with media types and the Instant Experts of the Internet psychoanalyzing what Warren Buffett, Bill Ackman, and Cathie Wood have been buying and selling.
I do not care what they are doing.
There are millions of eyeballs following every move of the best-known investors, which will leave little opportunity for gaining useful insights or creating an edge.
For the next several days, all the crackerjack-box Nuclear Engineers and global trade experts of Twitter will be experts in the reasons and beliefs that drive Warren and Bill to buy what they bought and sell what they sold.
I would rather follow those investors that are out of the limelight putting up steady returns that crush the markets and avoid the spotlight.
Being one of a small handful of people stealing ideas from a brilliant investor can still create a meaningful edge.
Robotti and Company is a great example of an out-of-the-limelight investment firm that has been quietly beating the market for decades. It is worth the time to go through the quarterly filings and see what gems we can uncover.
The Thundering Herd of the Web will not be in front of you and bid the shares up several points before you can finish your search.
They are not a hot money shop that owns the market darlings of the day and hold stocks for a long time, so most of you reading this will also ignore them.
Very few people active in the markets today will care for Robotti&#8217;s five-year average holding period.
When it comes to finding true value in the markets, few have demonstrated the consistent discipline and unwavering commitment of Bob Robotti. What I&#8217;ve always admired about Robotti&#8217;s approach is that it isn&#8217;t flashy or complicated &#8211; it&#8217;s simply buying good businesses at bargain prices and having the patience to let the market eventually recognize their worth.
Robotti&#8217;s story is a perfect example of how focusing on fundamentals can build a successful investment career. After graduating from Bucknell University and earning his MBA in Accounting from Pace University, he started in public accounting. This might seem like an unlikely beginning for an investment legend, but those accounting skills would become the foundation of his analytical approach.
The turning point in Robotti&#8217;s career came during an audit assignment for Tweedy Browne, where conversations with Joe Reilly Sr. introduced him to value investing principles.
Think about that &#8211; while most young professionals were just trying to get their work done, Robotti was absorbing wisdom from a partner at one of the most respected value shops on Wall Street.
That&#8217;s how real investing education happens.
Before launching his own firm, Robotti cut his teeth as a vice president at Gabelli &amp; Company. Working alongside another value investing legend in Mario Gabelli surely sharpened his skills.
In 1983, Robotti partnered with Dan Eng to launch Robotti &amp; Eng, Inc. Their initial focus was uncovering undervalued opportunities in pink sheet equities.
This wasn&#8217;t glamorous work &#8211; they were digging through the market&#8217;s bargain bin while everyone else was chasing the hot stocks of the day.
The firm eventually evolved into Robotti &amp; Company, expanding their offerings while never abandoning their core value philosophy.
What&#8217;s remarkable about Robotti&#8217;s investment approach is its consistency. For over 40 years, he&#8217;s stuck to the classic Benjamin Graham principles that markets frequently misprice securities. While others chased quarterly estimates and momentum plays, Robotti focused on understanding businesses&#8217; normalized earnings power before the market caught on.
The lesson from Robotti&#8217;s career is straightforward: buy good businesses at bargain prices, focus on the long term, and ignore market noise. While everyone else is chasing the latest fad, deep value investors like Robotti quietly compound wealth year after year.
In a market dominated by AI, crypto, and whatever else CNBC is hyping this week, Robotti&#8217;s patient, disciplined approach is refreshing. Find businesses trading below intrinsic value, understand what the market is missing, and wait. That&#8217;s how real wealth is built in the stock market, and Bob Robotti has proven it for four decades.
Here are the top three largest purchases by Robotti and Company in the first quarter of 2025:
Tidewater Inc. (Ticker: TDW) is the global leader in offshore support vessels, serving the international energy industry with a fleet of workboats that transport crews, equipment, and supplies to offshore drilling platforms and production facilities. The company operates primarily in deepwater and harsh environment markets, with a presence in every major offshore basin, including the U.S. Gulf of Mexico, West Africa, the North Sea, and Southeast Asia.
Following a successful post-bankruptcy restructuring, Tidewater has refocused on disciplined capital allocation, maintaining one of the youngest and most capable fleets in the industry. With improving offshore exploration and production activity, tight vessel supply, and growing demand for high-spec tonnage, Tidewater is positioned to benefit from rising day rates and extended contract durations. The company has low leverage, strong free cash flow generation, and significant operating leverage as vessel utilization recovers, making it a compelling deep-value play for investors with a long-term horizon on offshore energy markets.
Robotti is obviously bullish on the offshore oil and gas business as he also was a buyer of SEACOR Marine Holdings (Ticker: SMHI).
SEACOR is one of those under-the-radar names that&#8217;s quietly critical to keeping the offshore energy world spinning. Based out of Houston, SEACOR runs a global fleet of support vessels—platform supply boats, fast crew movers, and liftboats that haul people, gear, and equipment out to oil rigs and wind installations all over the world. If something&#8217;s happening offshore, there&#8217;s a decent chance a SEACOR boat is nearby helping make it happen.
The business leans heavily into safety, reliability, and increasingly, greener operations. They&#8217;ve got a solid footprint in every major offshore basin, serving big-name oil companies, independents, and even the offshore wind crowd. It&#8217;s a gritty, asset-heavy business, but SEACOR&#8217;s diversified fleet and global reach give it staying power.
Legacy Housing Corporation (Ticker: LEGH) is one of those quietly solid businesses that doesn&#8217;t make a lot of headlines, but it keeps chugging along, making money and filling a real need. Headquartered in Bedford, Texas, Legacy is the fourth-largest manufacturer of mobile and tiny homes in the U.S., with a stronghold across the South.
They&#8217;ve been at it since 2005, and their model is pretty simple. They build affordable homes, sell them through a network of company stores and independent dealers, and offer financing so folks can actually afford them.
What sets Legacy apart is how integrated their business is. They manufacture the homes themselves, finance them, and even sell directly to communities and consumers. That vertical setup keeps margins healthy, and you can see it in the numbers.
While revenue dipped slightly in 2024 to $184 million, net income jumped over 13% to $61.6 million. That&#8217;s thanks to some smart moves on the finance side and keeping expenses under control.
In a world where affordable housing is in short supply and demand just keeps rising, Legacy Housing looks like a business that&#8217;s built to last and to keep throwing off cash along the way.
These three stocks will not be ranked at the top of today&#8217;s social media searches.
They will not get much, if any, airtime on CNBC or Fox Business.
They are, however, solid companies trading at bargain prices that could deliver huge gains over the next several years.

Opinion

LEGH

SMHI

Alpha Buying: Why Smart Money Is Moving Into Offshore and Affordable Housing

<a href="https://www.bloomberg.com/news/articles/2025-05-15/cvs-bids-for-rite-aid-stores-patient-files-in-pacific-northwest?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-05-15/cvs-bids-for-rite-aid-stores-patient-files-in-pacific-northwest?embedded-checkout=true</a>

'CVS Bids For Rite Aid Stores, Patient Files in Pacific Northwest'- Bloomberg

Oppenheimer analyst Colin Rusch maintains Aeva Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEVA#NASDAQ">AEVA</a>) with a Outperform and raises the price target from $9 to $18.

AEVA

Oppenheimer Maintains Outperform on Aeva Technologies, Raises Price Target to $18

Oppenheimer analyst Jay Olson maintains Jasper Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JSPR#NASDAQ">JSPR</a>) with a Outperform and lowers the price target from $80 to $65.

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

Oppenheimer Maintains Outperform on Jasper Therapeutics, Lowers Price Target to $65

Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) is catching traders' attention again as its current price action closely resembles a major historical pattern that led to <a href="https://www.benzinga.com/money/dogecoin-doge-price-prediction">explosive gains in the past</a>.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.2282</td>
<td>-1.2%</td>
<td>+19.7%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001519</td>
<td>-2.9%</td>
<td>+9%</td>
</tr>
<tr>
<td>Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td>$0.00001396</td>
<td>+1.8%</td>
<td>+36.6%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Trader Tardigrade dubbed this setup "Dogecoin Super Cycle 2," suggesting DOGE is at a key accumulation phase similar to the lead-up before its massive 2021 rally. 
Drawing parallels to the 2014–2018 macro pattern, Tardigrade believes the current structure implies substantial upside in the coming months.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Dogecoin?src=hash&amp;ref_src=twsrc%5Etfw">#Dogecoin</a> repeats the macro chart pattern in 2014-2018 &#x1f525;<a href="https://twitter.com/search?q=%24Doge&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$Doge</a> <a href="https://t.co/IoUwomhopW">pic.twitter.com/IoUwomhopW</a>
&mdash; Trader Tardigrade (@TATrader_Alan) <a href="https://twitter.com/TATrader_Alan/status/1923015587145580923?ref_src=twsrc%5Etfw">May 15, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
According to Bitcoinsensus, DOGE has already <a href="https://x.com/Bitcoinsensus/status/1923004315431518255">broken</a> out of a falling wedge, a bullish continuation pattern, and is now consolidating within a bull flag. The next technical target is $0.305, based on the measured move from the wedge breakout.
Similarly, Bluntz Capital <a href="https://x.com/Bluntz_Capital/status/1922845477512372626">remains</a> bullish, noting a classic inverse head and shoulders pattern with strong breakout volume. 
The ongoing pullback, he said, is healthy and could set the stage for further upside.
Statistics: Coinglass data shows Dogecoin liquidations in the past 24 hours stands at $13.4 million with long liquidations of $10.7 million. Open interest spiked to $3.03 billion.
Community News: In a recent post, 21Shares <a href="https://x.com/21Shares/status/1923021667254542341">highlighted</a> Dogecoin's cultural relevance, noting it "captures the spirit of the internet—from powering payments to supporting global causes."
The 21Shares Dogecoin ETP currently manages $2.15 million in assets, with a NAV of $7.66 as of May 14. The fund has returned 53.3% YTD, with a 2.2% daily gain.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45348013/dogecoin-jumps-4-can-doge-hit-1-soon">Dogecoin Jumps 4%: Can DOGE Hit $1 Soon?</a></li>
</ul>
Image: Shutterstock

$DOGE

$PEPE

$SHIB

Dogecoin Down 1% But This Pattern Signals A Breakout Is Imminent

Federal court jury found Amgen liable for violating antitrust and tort laws by using cross-therapeutic bundled rebates to prevent Praluent&#xAE; (alirocumab) from competing in the market
Jury awarded Regeneron $135.6 million dollars of compensatory damages and $271.2 million dollars in punitive damages
TARRYTOWN, N.Y., May 15, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) applauds the jury verdict in the U.S. District Court for the District of Delaware that found that Amgen Inc. violated antitrust and tort laws by creating a bundling scheme that illegally leveraged its blockbuster anti-inflammatory drugs Enbrel&#xAE; (etanercept) and Otezla&#xAE; (apremilast) to convince pharmacy benefit managers (PBMs) to select Repatha&#xAE; (evolocumab) as the exclusive PCSK9 category product over Praluent&#xAE; (alirocumab). The jury found that Amgen violated the Clayton Act, the Sherman Act, the New York State Donnelly Act, the California Cartwright Act and Delaware tort law.
Enbrel and Otezla are therapeutically different medicines that do not treat the heart conditions that Praluent or Repatha address. Amgen threatened to withhold rebates unless PBMs preferred Repatha and excluded Praluent. Amgen prevented Regeneron from competing on a level playing field and unfairly denied patients access to Praluent. This anticompetitive practice shut out an innovative therapy from the PCSK9 marketplace, not based on clinical merit or price. Because of Amgen's size and unrelated product portfolio, their anticompetitive actions ultimately hurt competition and patients.
The jury awarded Regeneron $135.6 million dollars of compensatory damages. The jury also awarded Regeneron $271.2 million dollars in punitive damages. Punitive damages may be awarded to punish a party for outrageous conduct and deter a party, and others like it, from engaging in similar conduct in the future.

REGN

Regeneron Pharma: Federal Court Jury Found Amgen Liable For Violating Antitrust And Tort Laws By Using Cross-Therapeutic Bundled Rebates To Prevent Praluent From Competing In Market; Jury Awarded Regeneron $135.6M Of Compensatory Damages And $271.2M In Punitive Damages

Needham analyst Mike Matson maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Buy and raises the price target from $100 to $108.

MMSI

Needham Maintains Buy on Merit Medical Systems, Raises Price Target to $108

Oppenheimer analyst Jeff Jones maintains Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) with a Outperform and lowers the price target from $26 to $25.

ALMS

Oppenheimer Maintains Outperform on Alumis, Lowers Price Target to $25

Press Releases

Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval

Earnings

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

Small Cap

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

Offerings

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Contracts

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock

Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update

CTOR

CTXR

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics

Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Hldgs

Athira Pharma

Aytu BioPharma

Biofrontera

Cingulate

Cocrystal Pharma

Citius Pharmaceuticals

Evoke Pharma

Gelteq

Hoth Therapeutics

Impact BioMedical

Jaguar Health

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lipocine

Lyra Therapeutics

Purple Biotech Ltd. - American Depositary Shares

Purple Biotech

ProPhase Labs

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

SenesTech

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals

Talphera

Traws Pharma

Titan Pharmaceuticals, Inc. - Common Stock

Titan Pharma

TherapeuticsMD

D. Boral Capital

HC Wainwright & Co.

EF Hutton

Screenshot 2024-08-06 at 7.17.40 PM

Biotech

TENK

Citius Pharmaceuticals To Receive 65 Million Shares Of TenX Keane For Merger Of Citius Oncology

Screenshot 2024-07-29 at 8.39.42 PM

From fighting cancer to treating bloodstream infections, Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is busy trying to solve some of the world&#39;s ills. That&#39;s picking up steam with two of its lead products close to commercialization. 

Citius Pharmaceuticals Nears Market Breakthrough With Two Leading Products

Screenshot 2024-07-24 at 5.43.01 PM

Interview

This Pharma Company Is Preparing To Launch Its Lead Candidate

Screenshot 2024-04-17 at 5.34.28 PM

Citius Pharmaceuticals (NASDAQ: CTXR) Advances Oncology Asset, Paving Way For Spin Out Of Advanced T-cell Lymphoma Treatment

Citius Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 EPS results.

Comments

Citius Pharmaceuticals

ニュース

最新ニュース Citius Pharmaceuticals (NASDAQ:CTXR) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル